Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.37 -1.72 (-3.07%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock
NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity. 
Via Chartmill
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy. 
Via Benzinga
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?
Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop... 
Via Stocktwits
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs. 
Via Investor's Business Daily
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
NVO LAWSUIT ALERT: Levi &amp; Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears
Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks. 
Via Benzinga
Stevens Capital Closes Out Position in Eli Lilly
Via The Motley Fool
2 Dividend Stocks to Hold for the Next 10 Years
These stocks offer more than just dividends. 
Via The Motley Fool
Topics Economy
2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
It doesn't take much to get your money to start working for you on Wall Street. 
Via The Motley Fool
Market Movers: Unpacking the Forces Behind Recent Stock Swings
The financial markets have been a dynamic arena recently, showcasing significant and often dramatic movements in individual stock valuations. These shifts are not random but are deeply rooted in... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Why Novo Nordisk Stock Tumbled on Tuesday
A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy. 
Via The Motley Fool
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.